Your session is about to expire
← Back to Search
Alkylating agents
Carboplatin for Small Cell Lung Cancer
Phase 2
Waitlist Available
Led By Jing Zeng
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial is testing how well radiation therapy works after chemo and immunotherapy to shrink tumors in patients with stage IV small cell lung cancer.
Eligible Conditions
- Extensive-stage Small Cell Lung Cancer
- Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression free survival
Secondary outcome measures
Healthcare related quality of life: EORTC QLQ-C30
Healthcare related quality of life: EORTC QLQ-LC13
Incidence of grade 2 or higher pneumonitis
+2 moreSide effects data
From 2022 Phase 3 trial • 1301 Patients • NCT0303810060%
ALOPECIA
51%
NAUSEA
45%
ARTHRALGIA
44%
ANAEMIA
38%
FATIGUE
35%
HYPERTENSION
35%
CONSTIPATION
35%
DIARRHOEA
30%
NEUTROPENIA
28%
PERIPHERAL SENSORY NEUROPATHY
28%
ABDOMINAL PAIN
28%
NEUTROPHIL COUNT DECREASED
24%
NEUROPATHY PERIPHERAL
24%
RASH
23%
HEADACHE
23%
VOMITING
22%
WHITE BLOOD CELL COUNT DECREASED
22%
MYALGIA
21%
PROTEINURIA
21%
EPISTAXIS
21%
PLATELET COUNT DECREASED
21%
THROMBOCYTOPENIA
19%
DECREASED APPETITE
18%
HYPOTHYROIDISM
17%
URINARY TRACT INFECTION
16%
COUGH
16%
PYREXIA
15%
STOMATITIS
14%
HYPOMAGNESAEMIA
14%
ASPARTATE AMINOTRANSFERASE INCREASED
14%
BACK PAIN
14%
INSOMNIA
14%
ALANINE AMINOTRANSFERASE INCREASED
14%
DYSPNOEA
14%
PRURITUS
13%
WEIGHT DECREASED
13%
PAIN IN EXTREMITY
12%
DIZZINESS
12%
INFUSION RELATED REACTION
12%
ASTHENIA
11%
LEUKOPENIA
11%
HYPOKALAEMIA
10%
UPPER RESPIRATORY TRACT INFECTION
9%
DYSGEUSIA
8%
ABDOMINAL PAIN UPPER
8%
FEBRILE NEUTROPENIA
8%
HYPOAESTHESIA
8%
WEIGHT INCREASED
8%
HYPERTHYROIDISM
7%
BONE PAIN
7%
LYMPHOCYTE COUNT DECREASED
7%
DYSPHONIA
7%
MUCOSAL INFLAMMATION
7%
MUSCULAR WEAKNESS
7%
HYPONATRAEMIA
7%
PARAESTHESIA
7%
OROPHARYNGEAL PAIN
7%
DYSPEPSIA
7%
RASH MACULO-PAPULAR
7%
HYPERGLYCAEMIA
6%
BLOOD ALKALINE PHOSPHATASE INCREASED
6%
OEDEMA PERIPHERAL
6%
NASOPHARYNGITIS
6%
ABDOMINAL DISTENSION
6%
ANXIETY
5%
PAIN
5%
DEPRESSION
5%
DRY MOUTH
5%
MALAISE
5%
NASAL CONGESTION
5%
VISION BLURRED
5%
DRY SKIN
5%
URTICARIA
5%
HOT FLUSH
5%
NECK PAIN
4%
GASTROOESOPHAGEAL REFLUX DISEASE
2%
ILEUS
2%
PNEUMONIA
2%
PULMONARY EMBOLISM
2%
COLITIS
2%
SMALL INTESTINAL OBSTRUCTION
1%
PERITONITIS
1%
LIVER INJURY
1%
INTESTINAL OBSTRUCTION
1%
UROSEPSIS
1%
DEHYDRATION
1%
TRANSIENT ISCHAEMIC ATTACK
1%
PNEUMONITIS
1%
ABDOMINAL ABSCESS
1%
INFECTED LYMPHOCELE
1%
PYELONEPHRITIS
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo With Paclitaxel, Carboplatin and Bevacizumab
Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (durvalumab, chemotherapy, radiation therapy)Experimental Treatment7 Interventions
INDUCTION: Patients receive standard of care chemotherapy consisting of carboplatin or cisplatin and etoposide. Patients also receive durvalumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive durvalumab IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning cycle 5 or 6 of durvalumab, patients undergo hypofractionated radiation therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cisplatin
2013
Completed Phase 3
~1940
Durvalumab
2017
Completed Phase 2
~3870
Carboplatin
2014
Completed Phase 3
~6670
Etoposide
2010
Completed Phase 3
~2440
Hypofractionated Radiation Therapy
2016
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
University of WashingtonLead Sponsor
1,739 Previous Clinical Trials
1,847,928 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,262 Previous Clinical Trials
288,595,242 Total Patients Enrolled
Jing ZengPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium
7 Previous Clinical Trials
110 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of cancer spreading to the fluid around the brain and spinal cord.You have had another type of cancer in the past, except for: [list specific exceptions].You have received an organ transplant from someone else in the past.You have an autoimmune condition affecting your peripheral nervous system that requires treatment with medications that affect your whole body or have symptoms indicating your peripheral nervous system is getting worse.You have vitiligo or alopecia (hair loss).You have an underactive thyroid (hypothyroidism) but it is being treated with hormone replacement therapy and it is stable.You have a long-term skin condition that can be managed without needing medication throughout your entire body.It's okay if you have taken steroids before chemotherapy, but if you have taken steroids as a premedication for other reasons (like CT scans), you may not be eligible.You have not received any cancer treatments, such as chemotherapy, hormone therapy, or other immunotherapies, for at least 4 months before being diagnosed with ES-SCLC.You have a medical condition that makes it unsafe for you to take platinum and etoposide medications.You have a history of a weak immune system that doesn't work properly.You are using steroid medications through your nose, inhaler, on your skin, or through local injections.You have celiac disease but it is controlled by following a specific diet.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (durvalumab, chemotherapy, radiation therapy)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any additional investigations into the efficacy of Carboplatin?
"At present, 455 Phase 3 trials studying the effects of Carboplatin are in progress. The majority of these research sites are located in Shanghai, yet there still exists nearly 8 thousand other locations worldwide that seek to analyse this medication's efficacy."
Answered by AI
Is there currently an opportunity to join this research endeavor?
"Affirmative. Clinicaltrials.gov attests that this medical trial is actively looking for participants, with the first post dating back to December 28th 2022 and most recent modifications occurring on November 28th 2022. 50 subjects are sought at a single testing site."
Answered by AI
What medical problems does Carboplatin commonly relieve?
"While commonly prescribed for Hodgkin's Disease, Carboplatin can also be a viable treatment option for malignant pleural mesothelioma, advanced head and neck cancer, as well as other serious diseases."
Answered by AI
What is the current participant count in this research endeavor?
"Affirmative. Information available on clinicaltrials.gov suggests this investigation is actively seeking trial volunteers; it was initially posted in late December 2022 and last edited towards the end of November that same year. The research requires 50 participants at a single site."
Answered by AI
Can you enumerate the potential perils of Carboplatin administration?
"Given the Phase 2 status of the trial, there is evidence suggesting this drug's safety but not its efficacy. Therefore, our team assigned a score of 2 to Carboplatin on their safety scale."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger